Eli Lilly and Company (NYSE:LLY) Reaches New 12-Month High - What's Next?

Key Points

• Eli Lilly shares hit a new 52-week high, trading as high as $1,149.10 as investors continued to bid up the stock on strong momentum in the pharma giant.
• Key catalysts include expanding access to Zepbound and a major vaccines push: CVS Caremark restored coverage for Lilly’s obesity drug and will cover its new obesity pill on standard plans, while Lilly also announced a $3.83 billion deal to buy three vaccine developers.
• Wall Street remains bullish despite the run-up, with multiple analysts raising price targets and the consensus still sitting at a “Moderate Buy” with a $1,227 average target.

Eli Lilly and Company (NYSE:LLY - Get Free Report) shares hit a new 52-week high during trading on Thursday . The company traded as high as $1,149.10 and last traded at $1,134.1640, with a volume of 1665116 shares traded. The stock had previously closed at $1,082.92.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Caremark said it is restoring coverage for Lilly’s blockbuster obesity drug Zepbound and will also cover Lilly’s new obesity pill on standard plans, improving access for millions of patients and reinforcing Lilly’s dominance in the GLP-1 market. Reuters article
• Positive Sentiment: The company announced a $3.83 billion deal to buy three vaccine developers, signaling a major expansion into infectious disease and giving investors a potential new long-term growth engine beyond obesity and diabetes. CNBC article
• Positive Sentiment: Analysts remain upbeat, with reports citing BofA lifting its price target and Wolfe Research reiterating an Outperform rating, which supports the stock’s momentum after recent record highs. Insider Monkey article

Wall Street Analysts Forecast Growth

A number of brokerages have commented on LLY. Weiss Ratings cut Eli Lilly and Company from a "buy (b)" rating to a "buy (b-)" rating in a research report on Tuesday, May 19th. Cantor Fitzgerald lifted their price target on Eli Lilly and Company from $1,205.00 to $1,230.00 and gave the stock an "overweight" rating in a research report on Friday, May 1st. TD Cowen lifted their price target on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a "buy" rating in a research report on Thursday, January 29th. Truist Financial reissued a "buy" rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Finally, Sanford C. Bernstein restated an "outperform" rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus price target of $1,227.00.

Eli Lilly and Company Stock Performance

The stock has a market capitalization of $1.06 trillion, a price-to-earnings ratio of 40.00, a price-to-earnings-growth ratio of 1.16 and a beta of 0.48. The firm has a fifty day moving average of $948.23 and a 200 day moving average of $1,007.67. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping the consensus estimate of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, May 15th. Eli Lilly and Company's payout ratio is currently 24.58%.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently modified their holdings of the business. Norges Bank acquired a new stake in Eli Lilly and Company in the 4th quarter worth about $12,976,634,000. Capital Research Global Investors boosted its holdings in Eli Lilly and Company by 20.9% in the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company's stock worth $19,141,787,000 after buying an additional 4,332,008 shares during the last quarter. J. Stern & Co. LLP boosted its holdings in Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company's stock worth $4,047,245,000 after buying an additional 4,038,502 shares during the last quarter. Cardano Risk Management B.V. boosted its holdings in Eli Lilly and Company by 876.1% in the 4th quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company's stock worth $2,552,419,000 after buying an additional 2,131,734 shares during the last quarter. Finally, Fifth Third Bancorp boosted its holdings in Eli Lilly and Company by 321.3% in the 1st quarter. Fifth Third Bancorp now owns 1,963,490 shares of the company's stock worth $1,805,959,000 after buying an additional 1,497,423 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.